Literature DB >> 17099876

Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment.

Shotaro Nakamura1, Takayuki Matsumoto, Hongtao Ye, Shigeo Nakamura, Hiroshi Suekane, Hiroshi Matsumoto, Takashi Yao, Masazumi Tsuneyoshi, Ming-Qing Du, Mitsuo Iida.   

Abstract

BACKGROUND: The majority of gastric mucosa-associated lymphoid tissue (MALT) lymphoma develops in Helicobacter pylori-associated chronic gastritis. Little is still known regarding the clinicopathologic features of gastric MALT lymphoma not associated with H. pylori infection.
METHODS: One hundred thirty-seven patients with gastric MALT lymphoma, in whom H. pylori status was evaluated using at least both serology and histology, were enrolled. Clinical, histopathologic, and molecular findings were compared between H. pylori-negative group (n = 12; 9%) and H. pylori-positive group (n = 125; 91%). t(11;18)(q21;q21) was investigated by reverse-transcription polymerase chain reaction and interphase fluorescence in situ hybridization.
RESULTS: In cases without diffuse large B-cell lymphoma (DLBCL) component, H. pylori-negative lymphomas located more frequently in the proximal stomach (70%), less frequently appeared as superficial type (40%), and frequently invaded the submucosa or beyond (70%). Histologically, lymphoepithelial lesions (57%), lymphoid follicles (43%), and background mucosal atrophy (50%) in the H. pylori-negative group were less frequent than in the H. pylori-positive group (91%, 93%, and 100%, respectively). The frequencies of t(11;18)(q21;q21) (100%) and BCL10 nuclear expression (100%) in the H. pylori-negative group were significantly higher than in the H. pylori-positive group (2% and 27%, respectively). Response to antibiotic treatment was observed not only in the H. pylori-positive group (75%), but also in the H. pylori-negative group (2 of 7 patients, 29%). In cases with a DLBCL component, such differences were not observed between the 2 groups.
CONCLUSIONS: H. pylori-negative gastric MALT lymphoma is characterized by frequent t(11;18)(q21;q21). Antibiotic treatment should be considered also for this disease, although cases with t(11;18)(q21;q21) may need additional strategies. Copyright 2006 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17099876     DOI: 10.1002/cncr.22326

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Updated Review of Clinical Outcomes and the Molecular Pathogenesis.

Authors:  Hidekazu Suzuki; Yoshimasa Saito; Toshifumi Hibi
Journal:  Gut Liver       Date:  2009-06-30       Impact factor: 4.519

Review 2.  Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review.

Authors:  Naoki Asano; Katsunori Iijima; Tomoyuki Koike; Akira Imatani; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

3.  Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma.

Authors:  Hyung Soon Park; Yu Jin Kim; Woo Ick Yang; Chang Ok Suh; Yong Chan Lee
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

4.  A case of Helicobacter heilmannii-associated primary gastric mucosa-associated lymphoid tissue lymphoma achieving complete remission after eradication.

Authors:  Takuma Okamura; Yugo Iwaya; Shuichi Yokosawa; Tomoaki Suga; Norikazu Arakura; Takehisa Matsumoto; Naoko Ogiwara; Kayoko Higuchi; Hiroyoshi Ota; Eiji Tanaka
Journal:  Clin J Gastroenterol       Date:  2013-01-09

Review 5.  Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication.

Authors:  Qing Guo; Shanqi Guo; Yizhuo Zhang
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

6.  Frequency of Helicobacter pylori and CagA antibody in patients with gastric neoplasms and controls: the Indian enigma.

Authors:  Uday C Ghoshal; Shridhar Tiwari; Sadhna Dhingra; Rakesh Pandey; Ujjala Ghoshal; Shweta Tripathi; Himani Singh; V K Gupta; A K Nagpal; Sita Naik; Archana Ayyagari
Journal:  Dig Dis Sci       Date:  2008-03-20       Impact factor: 3.199

Review 7.  Helicobacter pylori and gastric mucosa-associated lymphoid tissue lymphoma: recent progress in pathogenesis and management.

Authors:  Shotaro Nakamura; Takayuki Matsumoto
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

8.  Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation.

Authors:  Shotaro Nakamura; Hongtao Ye; Chris M Bacon; Alison Goatly; Hongxiang Liu; Alison H Banham; Roland Ventura; Takayuki Matsumoto; Mitsuo Iida; Yutaka Ohji; Takashi Yao; Masazumi Tsuneyoshi; Ming-Qing Du
Journal:  Gut       Date:  2007-05-24       Impact factor: 23.059

Review 9.  The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas.

Authors:  Laahn H Foster; Craig A Portell
Journal:  Curr Treat Options Oncol       Date:  2015-06

10.  Molecular Aspects of H. pylori-Related MALT Lymphoma.

Authors:  Scott R Owens; Lauren B Smith
Journal:  Patholog Res Int       Date:  2011-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.